Why is MannKind stock surging today?

⦿ Executive Snapshot

What: MannKind stock surged by +39.28% following the announcement of a new ralinepag dry powder inhalation (DPI) development program in partnership with United Therapeutics Corporation.
Who: MannKind Corporation and United Therapeutics Corporation.
Why it matters: This partnership potentially unlocks significant financial milestones for MannKind, reflecting investor confidence in the commercial viability of their new drug formulation amidst a positive market backdrop.

MannKind announced it is developing a dry powder inhalation formulation of ralinepag, known as MNKD-1501, for United Therapeutics under an expanded collaboration agreement.
MannKind is eligible to receive up to $35 million in development milestones plus 10% royalties on net sales from the ralinepag DPI program.
The original 2018 agreement with United Therapeutics led to the successful development and FDA approval of Tyvaso DPI, which generated $1.3 billion in revenue in 2025.
The announcement comes after United Therapeutics reported that its Phase 3 ADVANCE OUTCOMES study met its primary endpoint, enhancing the credibility of the new DPI program.
Prior analyst coverage was mixed, with H.C. Wainwright lowering its price target on MannKind from $11 to $8 while maintaining a Buy rating.

The partnership with United Therapeutics reframes MannKind's relationship as expansive, moving past previous challenges such as the introduction of TreSMI, which had negatively impacted MannKind's stock.
Historically, MannKind has relied on partnerships to drive innovation and market presence, with the ralinepag DPI program seen as a pivotal step in their growth trajectory.

Immediate market consequences include a significant stock price increase due to renewed investor confidence in MannKind's product pipeline and financial outlook.
Long-term implications could see MannKind positioning itself as a key player in the pulmonary arterial hypertension market, potentially increasing its market share and revenue streams.

Potential regulatory hurdles concerning the approval and commercialization of the new DPI formulation could impact timelines and financial projections.
Increased competition from other inhalation therapies, particularly those introduced by United Therapeutics, may pose challenges to MannKind’s market positioning.

Upcoming milestones include the potential financial results report from MannKind on May 6, 2026, which could further influence investor sentiment.
Future developments in regulatory approvals for MNKD-1501 and market performance of Tyvaso DPI will be critical indicators of success or failure for MannKind's strategy.